Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006129 | 0.86 | SMN1; SMN2 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2PKM | |
| SCHEMBL1007761 | 0.84 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2PKM | |
| SCHEMBL6379773 | 0.70 | ALDH1A1 (0.36) | CYP1A2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL18665244 | 0.69 | NPSR1 (0.35) | CYP1A2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL18632627 | 0.66 | ERCC1 (0.31) | — | |
| SCHEMBL1007694 | 0.65 | ADORA2A (0.31) | — | |
| SCHEMBL1007598 | 0.64 | SMN1; SMN2 (0.35) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL20400203 | 0.62 | NLRP3 (0.38) | CYP1A2MEN1KMT2AGAAALDH1A1 | |
| SCHEMBL1006748 | 0.62 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1557959 | 0.61 | L3MBTL1 (0.67) | CYP1A2MEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | CYP1A2 2476/4885MEN1 1454/4885KMT2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.